08:36 AM EDT, 08/08/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) reported Q2 non-GAAP net income Thursday of $0.06 per diluted share, swinging from a loss of $0.07 a year earlier.

Analysts polled by Capital IQ expected normalized earnings of $0.02.

Sales for the quarter ended June 30 were $126.7 million, up from $94.5 million a year earlier.

Analysts surveyed by Capital IQ expected $121.2 million.

The biotechnology company said it now expects 2024 revenue to grow 26% to 31%, compared with its prior growth guidance range of 25% to 30%.

Shares of the company were up 8% in recent Thursday premarket activity.

Price: 10.80, Change: +0.80, Percent Change: +8.00